Change in management at AbbVie

• Mag. Ute Van Goethem takes over the position of Managing Director of AbbVie in Austria.
• Mag. Ingo Raimon, General Manager, is saying goodbye to his well-deserved retirement after more than 35 years.

Mag. Ute Van Goethem is appointed Managing Director of AbbVie in Austria. She succeeds Mag. Ingo Raimon, who will be entering his well-deserved retirement on March 31st after more than 35 years.

Mag. Ute Van Goethem joined AbbVie in Germany in 2020 as Business Unit Director Hematology/Oncology and has been responsible for the entire division in Europe as Commercial Director Oncology since 2023. Before AbbVie, Mag. Ute Van Goethem was Country Head at Mundipharma Austria. The experienced manager began her successful career in the pharmaceutical industry in 2003 after completing her business studies in Innsbruck. The native of Upper Austria is pleased to be able to help shape the pharmaceutical sector in Austria again as part of her role as General Manager.

“Together with the experienced leadership team and all employees at AbbVie Austria, I am committed to significantly improving the quality of life of people with chronic illnesses in particular by giving them access to AbbVie’s innovative products. I am looking forward to returning to Austria because I know the healthcare market and many decision-makers from my previous job. The experiences from my international functions help me to understand developments in the European context and to shape them in the best possible way for Austria.”explains Mag. Ute Van Goethem.

An experienced expert in the industry is going into his well-deserved retirement

Mag. Ingo Raimon, lawyer, began his career at Abbott in 1989 and worked there for over 20 years in various functions and countries – including the last 12 years as General Manager in Austria. In January 2013, Ingo Raimon took over the management of the biopharmaceutical company AbbVie, which bundles research-based pharmaceutical services after the separation from Abbott. He campaigned for the interests of the pharmaceutical industry for decades and was one of the founders of the FOPI forum for the research-based pharmaceutical industry in Austria. He was elected President of PHARMIG in May 2023, of which he had been a board member since 2013. Ingo Raimon was President of FOPI from January 2013 to December 2016 and from November 2017 to November 2020. “The last 12 years have been an exciting journey. It was about making AbbVie a success as a company and establishing it in the domestic market. Ute Van Goethem has many years of experience in the industry and has excellent knowledge of the Austrian healthcare system. I am convinced that the entire team is in the best hands with her and I am looking forward to my new phase of life. The topic of health will continue to play a role in this section, as I am happy to support initiatives in the healthcare system pro bono or on a voluntary basis to ensure good care for patients.”says Mag. Ingo Raimon.

About AbbVie
AbbVie (NYSE:ABBV) is a global research-based biopharmaceutical company. AbbVie is committed to delivering novel therapies for some of the world’s most complex and serious diseases and addressing the medical challenges of tomorrow. AbbVie aims to make a real difference in people’s lives and operates in several key therapeutic areas: immunology, oncology, neurology, ophthalmology and virology, as well as medical aesthetics with the Allergan Aesthetics portfolio. In Austria, AbbVie is represented in Vienna. In total, AbbVie employs around 50,000 people worldwide and 180 in Austria. Further information about the company can be found at www.abbvie.com and www.abbvie.at. Follow AbbVie on X or visit our profiles on Facebook or LinkedIn.